[디깅노트] K-바이오 '원 베스트 웨이'의 양면성

Korean biotech companies relying on single strategic approaches—whether early technology licensing or blockbuster drugs—now face investor scrutiny shifting from past success to future readiness. While their core technologies remain valued, the market increasingly demands structural diversity and multi-path growth strategies rather than repeating proven formulas. This marks a maturation of Korea's biotech valuation framework toward resilience and strategic breadth over concentrated excellence.